Postpartum Cardiomyopathy and Considerations for Breastfeeding
Laura Kearney1, Paul Wright2, Sadeer Fhadil2
1UK Drugs in Lactation Advisory Service.
Cardiac Failure Review
|September 13, 2018
Summary
Postpartum cardiomyopathy (PPCM) is a rare heart condition. Breastfeeding may be possible for mothers with PPCM if risks to the infant are carefully assessed and managed.
Area of Science:
- Cardiology
- Neonatal Medicine
- Pharmacology
Background:
- Postpartum cardiomyopathy (PPCM) is a rare form of heart failure affecting women during late pregnancy or postpartum.
- It presents as left ventricular systolic dysfunction, with variable clinical progression from rapid deterioration to spontaneous recovery.
- Limited evidence exists on the safety of heart failure medications transferred to infants via breastfeeding.
Purpose of the Study:
- To evaluate the safety and feasibility of breastfeeding for mothers diagnosed with postpartum cardiomyopathy.
- To provide guidance on risk assessment for infants exposed to maternal heart failure medications during breastfeeding.
- To emphasize the importance of informed decision-making regarding breastfeeding in PPCM patients.
Main Methods:
- Review of existing literature on PPCM, heart failure pharmacotherapy, and infant drug exposure during breastfeeding.
- Analysis of drug properties, including adverse effects, pediatric use, and pharmacokinetics.
- Development of a risk-benefit assessment framework for managing breastfeeding in PPCM mothers.
Main Results:
- Breastfeeding is often incorrectly discouraged due to scarce evidence on medication safety for infants.
- Informed risk assessment, considering drug properties and infant monitoring, can manage potential risks.
- Maternal treatment takes priority, but breastfeeding can often be supported with careful consideration.
Conclusions:
- Breastfeeding should not be routinely contraindicated in mothers with PPCM.
- Informed risk assessment and infant monitoring are crucial for safe breastfeeding practices.
- Continued international research is needed to establish the efficacy and safety of pharmacotherapy in PPCM and its implications for breastfeeding.
Related Concept Videos
01:30Cardiomyopathy II: Dilated Cardiomyopathy
575
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
575
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
496
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
496
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
552
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
552
01:22Design Consideration
580
Designing a structure involves a series of considerations, primarily the material's ultimate strength, calculated through tests that measure changes under increased force until the material reaches its breaking point or limit. The ultimate load, where the material breaks, is divided by its original cross-sectional area, resulting in the ultimate normal stress or strength. The ultimate shearing stress is another significant factor taken into account.
The factor of safety is another key...
The factor of safety is another key...
580
01:29Cardiomyopathy V: Interprofessional Care
459
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
459
01:25Cardiomyopathy I: Introduction and Classification
611
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
611